arXiv:2511. 19735v2 Announce Type: replace-cross Abstract: Randomized controlled trials (RCTs)have been the cornerstone of clinical evidence; however, their cost, duration, and restrictive eligibility criteria limit power and external validity.
arXiv:2606. 28692v1 Announce Type: new Abstract: Treatment reasoning underpins every therapeutic decision, integrating disease context, comorbidities, medications, contraindications, and evolving biomedical knowledge to select an appropriate therapy.
While automated research systems promise to accelerate empirical analysis, they are prone to silent failures: instances in which analysis code executes successfully yet relies on invalid causal assumptions. We present the Artificial Intelligence (AI)-based Epidemiology Research Assistant (ARA), a framework that makes these failures visible by explicitly encoding causal design principles, study-specific assumptions, and methodological constraints.
arXiv:2607. 21173v1 Announce Type: new Abstract: While automated research systems promise to accelerate empirical analysis, they are prone to silent failures: instances in which analysis code executes successfully yet relies on invalid causal assumptions.
arXiv:2607. 27224v1 Announce Type: cross Abstract: External and synthetic control arms (ECAs) are entering psychiatric drug development, but the field lacks a benchmark that evaluates the properties regulators care about: not only how accurately a method reconstructs untreated trajectories, but whether its uncertainty is calibrated, whether it is robust to the informative observation times common in mental-health records (sicker patients are seen more often), and what false-positive rate it induces in go/no-go trial decisions.
arXiv:2607. 21806v1 Announce Type: new Abstract: Predictive machine learning (ML) models are increasingly used to aid human decision-makers across various high-risk domains such as healthcare and criminal justice.
arXiv:2606. 19245v1 Announce Type: new Abstract: Artificial intelligence (AI) agents promise to accelerate drug discovery by compressing interpretation and decision-making loops, but practical deployment requires trusted evaluation on realistic program decisions.
arXiv:2605. 02050v2 Announce Type: replace-cross Abstract: This work establishes a framework for standardizing AI evaluation RCTs (sometimes called human uplift studies).
arXiv:2606. 31273v1 Announce Type: new Abstract: AI-assisted research has entered a stage in which the central question is not only whether systems can generate hypotheses, run experiments, or produce manuscripts, but whether their scientific claims are calibrated to the evidence that supports them.
arXiv:2608. 05235v1 Announce Type: cross Abstract: Research agents increasingly conduct multi-round machine-learning experiments in industrial recommendation settings and retain the resulting trajectories to guide later decisions.
arXiv:2606. 17113v1 Announce Type: new Abstract: Distinguishing causal adverse drug events (ADEs) from spurious correlations remains a central challenge in pharmacovigilance.
arXiv:2601. 20819v2 Announce Type: replace-cross Abstract: Machine learning predictions are increasingly used to supplement incomplete or costly-to-measure outcomes in fields such as biomedical research, environmental science, and social science.
arXiv:2510. 22298v2 Announce Type: replace-cross Abstract: Uncovering the causal mechanisms of complex real-world systems remains a significant challenge, as these systems often entail high data collection costs and involve unknown interventions.